Literature DB >> 22758917

Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Patrick J McEnaney1, Christopher G Parker, Andrew X Zhang, David A Spiegel.   

Abstract

Synthetic immunology, the development of synthetic systems capable of modulating and/or manipulating immunological functions, represents an emerging field of research with manifold possibilities. One focus of this area has been to create low molecular weight synthetic species, called antibody-recruiting molecules (ARMs), which are capable of enhancing antibody binding to disease-relevant cells or viruses, thus leading to their immune-mediated clearance. This article provides a thorough discussion of contributions in this area, beginning with the history of small-molecule-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies. Thus, we describe ARMs capable of targeting cancer, bacteria, and viral pathogens, along with some of the scientific discoveries that have resulted from their development. Research in this area underscores the many exciting possibilities at the interface of organic chemistry and immunobiology and is positioned to advance both basic and clinical science in the years to come.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22758917      PMCID: PMC3401898          DOI: 10.1021/cb300119g

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  165 in total

1.  Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting.

Authors:  Kannan P Naicker; Hengguang Li; Alonso Heredia; Haijing Song; Lai-Xi Wang
Journal:  Org Biomol Chem       Date:  2004-02-02       Impact factor: 3.876

2.  Vaccine manufacturing: challenges and solutions.

Authors:  Jeffrey B Ulmer; Ulrich Valley; Rino Rappuoli
Journal:  Nat Biotechnol       Date:  2006-11       Impact factor: 54.908

Review 3.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

4.  Environmental nitrophenols and autoimmunity.

Authors:  K Lauer
Journal:  Mol Immunol       Date:  1990-07       Impact factor: 4.407

5.  Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.

Authors:  C F Barbas; A Heine; G Zhong; T Hoffmann; S Gramatikova; R Björnestedt; B List; J Anderson; E A Stura; I A Wilson; R A Lerner
Journal:  Science       Date:  1997-12-19       Impact factor: 47.728

6.  Chemical generation of bispecific antibodies.

Authors:  Venkata R Doppalapudi; Jie Huang; Dingguo Liu; Ping Jin; Bin Liu; Lingna Li; Joel Desharnais; Crystal Hagen; Nancy J Levin; Michael J Shields; Michelle Parish; Robert E Murphy; Joselyn Del Rosario; Bryan D Oates; Jing-Yu Lai; Marla J Matin; Zemeda Ainekulu; Abhijit Bhat; Curt W Bradshaw; Gary Woodnutt; Richard A Lerner; Rodney W Lappe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

7.  Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

Authors:  F Carreiras; Y Denoux; C Staedel; M Lehmann; F Sichel; P Gauduchon
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

8.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

Review 9.  Display technologies: application for the discovery of drug and gene delivery agents.

Authors:  Anna Sergeeva; Mikhail G Kolonin; Jeffrey J Molldrem; Renata Pasqualini; Wadih Arap
Journal:  Adv Drug Deliv Rev       Date:  2006-10-06       Impact factor: 15.470

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more
  36 in total

Review 1.  Time for a change: addressing R&D and commercialization challenges for antibacterials.

Authors:  David J Payne; Linda Federici Miller; David Findlay; James Anderson; Lynn Marks
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-05       Impact factor: 6.237

2.  Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer.

Authors:  Sascha A Kristian; John H Hwang; Bradley Hall; Emma Leire; John Iacomini; Robert Old; Uri Galili; Charles Roberts; Kary B Mullis; Mike Westby; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2015-05-05       Impact factor: 4.599

3.  Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.

Authors:  Maxime Lecerf; Tobias Scheel; Anastas D Pashov; Annaelle Jarossay; Delphine Ohayon; Cyril Planchais; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

4.  Chemical biology: How to minimalize antibodies.

Authors:  Christoph Rader
Journal:  Nature       Date:  2015-02-05       Impact factor: 49.962

Review 5.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

6.  A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.

Authors:  Rebecca M Lim; Liang Rong; Anjie Zhen; Jianming Xie
Journal:  ACS Chem Biol       Date:  2020-07-28       Impact factor: 5.100

Review 7.  Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing.

Authors:  Annemiek Uvyn; Bruno G De Geest
Journal:  Chembiochem       Date:  2020-07-10       Impact factor: 3.164

Review 8.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

9.  Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

Authors:  Charles E Jakobsche; Christopher G Parker; Ran N Tao; Mariya D Kolesnikova; Eugene F Douglass; David A Spiegel
Journal:  ACS Chem Biol       Date:  2013-09-20       Impact factor: 5.100

10.  Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.

Authors:  James T Patterson; Henry D Wilson; Shigehiro Asano; Napon Nilchan; Roberta P Fuller; William R Roush; Christoph Rader; Carlos F Barbas
Journal:  Bioconjug Chem       Date:  2016-09-26       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.